Picture of MiMedx logo

MDXG MiMedx News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapContrarian

MiMedx Group Inc expected to post a loss of 8 cents a share - Earnings Preview

* MiMedx Group Inc  MDXG.OQ   MDXG.O  is expected to show a
rise
in quarterly revenue when it reports  results on November 2. 
    * The Marietta Georgia-based  company is expected to report 
a
5.8% increase in revenue to $66.728 million from $63.07 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. The company's guidance on January 10
2022, for the period ended September 30, was for revenue between
$72.54 million and $74.43 million.
    * ​Refinitiv's mean analyst estimate for MiMedx Group Inc is
for a
loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MiMedx
Group Inc
is $9​, above​ its last closing price of $2.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.05       -0.06      -0.11     Missed  -94.1
 Mar. 31 2022  -0.10       -0.10      -0.11     Missed  -10
 Dec. 31 2021  -0.02       -0.03      0.01      Beat    130​
 Sep. 30 2021  -0.08       -0.08      -0.04     Beat    50
 ​​Jun.        -0.08       -0.07      -0.03     Beat    59.1
 30 2021                                                
 Mar. 31 2021  -0.19       -0.19      -0.09     Beat    52.6​
 Dec. 31 2020  -0.05       -0.05      -0.17     Missed  -240
 This summary was machine generated November 1 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on MiMedx

See all news